Literature DB >> 20736451

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

Irina Velichutina1, Rita Shaknovich, Huimin Geng, Nathalie A Johnson, Randy D Gascoyne, Ari M Melnick, Olivier Elemento.   

Abstract

EZH2 is the catalytic subunit of the PRC2 Polycomb complex and mediates transcriptional repression through its histone methyltransferase activity. EZH2 is up-regulated in normal germinal center (GC) B cells and is implicated in lymphomagenesis. To explore the transcriptional programs controlled by EZH2, we performed chromatin immunoprecipitation (ChIP-on-chip) in GC cells and found that it binds approximately 1800 promoters, often associated with DNA sequences similar to Droso-phila Polycomb response elements. While EZH2 targets overlapped extensively between GC B cells and embryonic stem cells, we also observed a large GC-specific EZH2 regulatory program. These genes are preferentially histone 3 lysine 27-trimethylated and repressed in GC B cells and include several key cell cycle-related tumor suppressor genes. Accordingly, siRNA-mediated down-regulation of EZH2 in diffuse large B-cell lymphoma (DLBCL) cells resulted in acute cell cycle arrest at the G(1)/S transition and up-regulation of its tumor suppressor target genes. At the DNA level, EZH2-bound promoters are hypomethylated in GC B cells, but many of them are aberrantly hypermethylated in DLBCL, suggesting disruption of normal epigenetic processes in these cells. EZH2 is thus involved in regulating a specific epigenetic program in normal GCs, including silencing of antiproliferative genes, which may contribute to the malignant transformation of GC B cells into DLBCLs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736451      PMCID: PMC3012542          DOI: 10.1182/blood-2010-04-280149

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation.

Authors:  Giuseppina Caretti; Monica Di Padova; Bruce Micales; Gary E Lyons; Vittorio Sartorelli
Journal:  Genes Dev       Date:  2004-11-01       Impact factor: 11.361

Review 2.  Germinal centres: role in B-cell physiology and malignancy.

Authors:  Ulf Klein; Riccardo Dalla-Favera
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

3.  A universal framework for regulatory element discovery across all genomes and data types.

Authors:  Olivier Elemento; Noam Slonim; Saeed Tavazoie
Journal:  Mol Cell       Date:  2007-10-26       Impact factor: 17.970

4.  Promoter CpG methylation contributes to ES cell gene regulation in parallel with Oct4/Nanog, PcG complex, and histone H3 K4/K27 trimethylation.

Authors:  Shaun D Fouse; Yin Shen; Matteo Pellegrini; Steve Cole; Alexander Meissner; Leander Van Neste; Rudolf Jaenisch; Guoping Fan
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

5.  BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells.

Authors:  Ryan T Phan; Masumichi Saito; Katia Basso; Huifeng Niu; Riccardo Dalla-Favera
Journal:  Nat Immunol       Date:  2005-09-04       Impact factor: 25.606

6.  Reverse engineering of regulatory networks in human B cells.

Authors:  Katia Basso; Adam A Margolin; Gustavo Stolovitzky; Ulf Klein; Riccardo Dalla-Favera; Andrea Califano
Journal:  Nat Genet       Date:  2005-03-20       Impact factor: 38.330

7.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

Authors:  Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

8.  Genome-scale DNA methylation maps of pluripotent and differentiated cells.

Authors:  Alexander Meissner; Tarjei S Mikkelsen; Hongcang Gu; Marius Wernig; Jacob Hanna; Andrey Sivachenko; Xiaolan Zhang; Bradley E Bernstein; Chad Nusbaum; David B Jaffe; Andreas Gnirke; Rudolf Jaenisch; Eric S Lander
Journal:  Nature       Date:  2008-07-06       Impact factor: 49.962

9.  Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.

Authors:  Yutaka Kondo; Lanlan Shen; Alfred S Cheng; Saira Ahmed; Yanis Boumber; Chantale Charo; Tadanori Yamochi; Takeshi Urano; Koichi Furukawa; Bernard Kwabi-Addo; David L Gold; Yoshitaka Sekido; Tim Hui-Ming Huang; Jean-Pierre J Issa
Journal:  Nat Genet       Date:  2008-05-18       Impact factor: 38.330

10.  Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus.

Authors:  Anders M Lindroth; Yoon Jung Park; Chelsea M McLean; Gregoriy A Dokshin; Jenna M Persson; Herry Herman; Diego Pasini; Xavier Miró; Mary E Donohoe; Jeannie T Lee; Kristian Helin; Paul D Soloway
Journal:  PLoS Genet       Date:  2008-08-01       Impact factor: 5.917

View more
  127 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

2.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

Authors:  Damian B Yap; Justin Chu; Tobias Berg; Matthieu Schapira; S-W Grace Cheng; Annie Moradian; Ryan D Morin; Andrew J Mungall; Barbara Meissner; Merrill Boyle; Victor E Marquez; Marco A Marra; Randy D Gascoyne; R Keith Humphries; Cheryl H Arrowsmith; Gregg B Morin; Samuel A J R Aparicio
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

Review 3.  Epigenetic dysregulation in follicular lymphoma.

Authors:  Shamzah Araf; Jessica Okosun; Lola Koniali; Jude Fitzgibbon; James Heward
Journal:  Epigenomics       Date:  2015-12-23       Impact factor: 4.778

4.  A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.

Authors:  Soham D Puvvada; Hongli Li; Lisa M Rimsza; Steven H Bernstein; Richard I Fisher; Michael LeBlanc; Monika Schmelz; Betty Glinsmann-Gibson; Thomas P Miller; Anne-Marie Maddox; Jonathan W Friedberg; Sonali M Smith; Daniel O Persky
Journal:  Leuk Lymphoma       Date:  2016-01-12

5.  Cancer angiogenesis induced by Kaposi sarcoma-associated herpesvirus is mediated by EZH2.

Authors:  Meilan He; Wei Zhang; Thomas Bakken; Melissa Schutten; Zsolt Toth; Jae U Jung; Parkash Gill; Mark Cannon; Shou-Jiang Gao
Journal:  Cancer Res       Date:  2012-05-16       Impact factor: 12.701

6.  Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.

Authors:  Nyasha Chambwe; Matthias Kormaksson; Huimin Geng; Subhajyoti De; Franziska Michor; Nathalie A Johnson; Ryan D Morin; David W Scott; Lucy A Godley; Randy D Gascoyne; Ari Melnick; Fabien Campagne; Rita Shaknovich
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

Review 7.  Diffuse large B-cell lymphoma-treatment approaches in the molecular era.

Authors:  Mark Roschewski; Louis M Staudt; Wyndham H Wilson
Journal:  Nat Rev Clin Oncol       Date:  2013-11-12       Impact factor: 66.675

8.  FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.

Authors:  L Sehgal; R Mathur; F K Braun; J F Wise; Z Berkova; S Neelapu; L W Kwak; F Samaniego
Journal:  Leukemia       Date:  2014-04-03       Impact factor: 11.528

9.  Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-cell lymphoma survival and clonogenicity.

Authors:  X Zhao; T Lwin; X Zhang; A Huang; J Wang; V E Marquez; S Chen-Kiang; W S Dalton; E Sotomayor; J Tao
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

10.  Harnessing lymphoma epigenetics to improve therapies.

Authors:  Haopeng Yang; Michael R Green
Journal:  Blood       Date:  2020-11-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.